Directorio

In this study, everyone receives a medicine called EVOLVE104 through an IV, which means it goes into a vein. This is an open label study, so everyone knows the drug and dose they are getting. Each infusion takes about one hour, and doctors will watch you closely during the infusion and for up to two days after it, especially at the beginning. The first three doses are given one week apart. After that, the doses are given every week or every two weeks in 28 day cycles. Early doses may require staying in the hospital overnight and may start at a lower amount that increases slowly to help your body adjust. During the study, you will have regular checkups, blood tests, heart tests, scans every eight weeks, and eye exams. The study has different stages, including screening, treatment, end of treatment, and long term follow up. Screening can last up to 28 days and includes exams, blood tests, heart tests, eye exams, and scans to make sure you can join the study.

We are doing this study to find out if an experimental drug called XC001 (the study drug) is an effective option for people who have angina that is caused by coronary artery disease. We want to know if the study drug can provide relief when common, approved therapies have failed to do so. The study drug is made using an adenovirus (one of the causes of the common cold). The adenovirus in the study drug is genetically altered so it is able to deliver a protein called VEGF (vascular endothelial growth factor) to the heart and potentially spur the growth of new blood vessels.

In this study, people will get a new kind of eye transplant. They'll be randomly chosen (like flipping a coin) to get either a special treated cornea or a regular one. Doctors will check on them for 2 years after the transplant to see how they're doing and to watch for any side effects.

We are doing this study to evaluate an experimental technology called the Reprieve Decongestion Management System (the study device) for heart failure patients with fluid overload. The study device is designed to help people with heart failure feel better by removing extra fluid from their body quickly. The device is programmed to deliver an appropriate amount of medication at the right time to help people shed extra fluid through urination. We want to know if this device works better than the standard treatment. The standard treatment is to prescribe diuretics (medication to increase urination) at a specified dose and dosage schedule.